% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Molinskym:'re impressive! Wish there were more participants here. I received my first issue of MIT's Technology Review and after reading was impressed with what I was able to grasp about RNAi . You seem knowledgeable about the field and would appreciate any
      simplified explanation about what they do. Does ALNY's
      have any actual product or is it mostly intel;lectual property?
      Anyway I bought in today at 5.75. I think this is a good company to hold onto for awhile. They also seem on their way to profitability rather fast. Any thoughts?

      • 1 Reply to blimminy1
      • Hello,

        I think it seems to be a good company too and own a number of shares. However, that said, I'm not expert in this area, so I'm hoping the board will be visited by some who are.

        Most of what I've done so far is read about RNAi as performed by others (mainly researchers in academia and in the companies) as well as coverage of developments in the popular press, e.g., the links that I provided.

        It seems to me that ALNY and RNAI, which are competitors, are leading the charge in this area, by going after the so-called "low hanging fruit" (disease, such as advanced macular degeneration, for which getting the treatment material to the target and effectuating a desired response seems feasible.

        Other companies are working with RNAI too, such as CYTR, however, their prospects for success are challenged quite a bit more than in the low hanging fruit scenario, by the problem of delivery of the molecules in a stable manner to the disease. This, as I understand it, is difficult.

        In regard to all of these companies, it seems to me that for now they are all long term plays (several years out) and they almost certainly will need major collaborators to get to final product, as the cost of producing a new medicine from bench-top through FDA approval now approaches $500-$800 million per drug, and none of these companies have that kind of resource base, ergo the partnering we've seen so far.

        This could work both ways. Too costly to go it alone, but also there is the prospect of intermittent lucrative milestone payments and licensing arrangements as the effort progresses.

        I'm watching for any patent developments, though this isn't always a good bell weather, as patent applications typically don't show up on the Patent Office web site until many months after submittal.

        Right now I'm watching for various points to accumulate (dips in the stock price) and am also keeping an eye on Institutional buying, which seems to be nothing unusual at the moment.

        Good luck to you.

60.81-7.98(-11.60%)May 3 4:00 PMEDT